TimesSquare Capital Management LLC Purchases 175,975 Shares of Encompass Health Co. (NYSE:EHC)

TimesSquare Capital Management LLC lifted its position in shares of Encompass Health Co. (NYSE:EHC - Free Report) by 18.1% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,150,866 shares of the company's stock after purchasing an additional 175,975 shares during the period. Encompass Health accounts for 1.1% of TimesSquare Capital Management LLC's portfolio, making the stock its 26th largest holding. TimesSquare Capital Management LLC owned 1.15% of Encompass Health worth $76,786,000 at the end of the most recent reporting period.

Several other hedge funds have also bought and sold shares of EHC. Raymond James & Associates raised its stake in Encompass Health by 5.7% in the 3rd quarter. Raymond James & Associates now owns 164,936 shares of the company's stock worth $11,077,000 after purchasing an additional 8,952 shares in the last quarter. Verdence Capital Advisors LLC lifted its position in shares of Encompass Health by 7.1% during the 3rd quarter. Verdence Capital Advisors LLC now owns 5,580 shares of the company's stock valued at $375,000 after acquiring an additional 370 shares during the period. Strs Ohio raised its stake in Encompass Health by 8.5% in the third quarter. Strs Ohio now owns 153,252 shares of the company's stock valued at $10,292,000 after purchasing an additional 11,975 shares in the last quarter. Washington Capital Management Inc. bought a new position in Encompass Health in the 3rd quarter valued at about $571,000. Finally, Park Avenue Securities LLC bought a new stake in shares of Encompass Health during the 3rd quarter worth approximately $298,000. 97.25% of the stock is currently owned by institutional investors and hedge funds.

Encompass Health Trading Up 1.3 %

NYSE:EHC traded up $1.08 on Thursday, reaching $86.37. 503,823 shares of the stock traded hands, compared to its average volume of 665,236. Encompass Health Co. has a 1-year low of $57.55 and a 1-year high of $86.60. The company has a current ratio of 1.37, a quick ratio of 1.37 and a debt-to-equity ratio of 1.14. The company's 50 day moving average is $79.76 and its 200-day moving average is $72.05. The firm has a market capitalization of $8.70 billion, a price-to-earnings ratio of 23.27, a price-to-earnings-growth ratio of 1.30 and a beta of 0.92.

Encompass Health (NYSE:EHC - Get Free Report) last issued its quarterly earnings results on Wednesday, April 24th. The company reported $1.12 earnings per share for the quarter, topping analysts' consensus estimates of $0.93 by $0.19. The firm had revenue of $1.32 billion during the quarter, compared to the consensus estimate of $1.27 billion. Encompass Health had a return on equity of 18.01% and a net margin of 7.60%. The business's revenue was up 13.4% compared to the same quarter last year. During the same period last year, the business posted $0.88 EPS. Equities research analysts anticipate that Encompass Health Co. will post 4.1 EPS for the current fiscal year.

Encompass Health Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, July 15th. Stockholders of record on Monday, July 1st will be paid a $0.15 dividend. The ex-dividend date of this dividend is Friday, June 28th. This represents a $0.60 annualized dividend and a dividend yield of 0.69%. Encompass Health's dividend payout ratio is presently 16.22%.

Insiders Place Their Bets

In other news, CEO Mark J. Tarr sold 44,976 shares of the business's stock in a transaction dated Tuesday, April 30th. The shares were sold at an average price of $83.27, for a total transaction of $3,745,151.52. Following the completion of the sale, the chief executive officer now directly owns 554,098 shares of the company's stock, valued at $46,139,740.46. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. In other Encompass Health news, CEO Mark J. Tarr sold 44,976 shares of the firm's stock in a transaction on Tuesday, April 30th. The stock was sold at an average price of $83.27, for a total transaction of $3,745,151.52. Following the transaction, the chief executive officer now directly owns 554,098 shares in the company, valued at approximately $46,139,740.46. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Greg D. Carmichael bought 2,000 shares of the stock in a transaction dated Friday, May 3rd. The stock was purchased at an average price of $83.73 per share, with a total value of $167,460.00. Following the acquisition, the director now owns 17,050 shares of the company's stock, valued at $1,427,596.50. The disclosure for this purchase can be found here. Corporate insiders own 2.10% of the company's stock.

Analysts Set New Price Targets

Several equities research analysts have weighed in on EHC shares. Royal Bank of Canada restated an "outperform" rating and set a $83.00 target price on shares of Encompass Health in a research note on Friday, February 9th. Barclays lifted their price target on shares of Encompass Health from $101.00 to $108.00 and gave the company an "overweight" rating in a report on Thursday, April 25th. Mizuho upped their price target on shares of Encompass Health from $93.00 to $95.00 and gave the stock a "buy" rating in a report on Thursday, April 25th. Stephens restated an "overweight" rating and set a $85.00 price objective on shares of Encompass Health in a research report on Tuesday, January 16th. Finally, Truist Financial lifted their price target on Encompass Health from $82.00 to $86.00 and gave the company a "buy" rating in a research note on Friday, February 9th. Eight analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Buy" and an average target price of $90.29.

Encompass Health Company Profile

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.